Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Muscle protein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    177 result(s) found for: Muscle protein. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2019-003959-11 Sponsor Protocol Number: 1703001 Start Date*: 2020-05-25
    Sponsor Name:Vestre Viken Trust
    Full Title: MUscle Side-Effects of atorvastatin in coronary patients (MUSE) follow-up study
    Medical condition: Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptoms
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004872-47 Sponsor Protocol Number: NSAID2015 Start Date*: 2015-07-20
    Sponsor Name:Karolinska Institutet, Department of Laboratory Medicine, Clinical Physiology C1:82,Karolinska Univ. Hosp., Huddinge
    Full Title: The effects of COX-inhibiting drugs on skeletal muscle adaptations to resistance exercise in healthy adults.
    Medical condition: Human skeletal muscle adaptations to resistance exercise (non-disease related).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008208-42 Sponsor Protocol Number: 08/0168 Start Date*: 2009-06-26
    Sponsor Name:UCL - The Joint UCLH/UCL Comprehensive Biomedical Research Unit
    Full Title: A Randomised, Double-Blind Placebo-Controlled Pilot Study Assessing the Safety and Tolerability of Arimoclomol in Adult with Sporadic Inclusion Body Myositis
    Medical condition: The research project proposes to investigate Sporadic Inclusion Body Myositis (IBM). IBM is the commonest acquired disease of muscle affecting people aged 50 years and over. It is a progressive and...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066407 Inclusion body myositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000047-33 Sponsor Protocol Number: VitD-EX1.0 Start Date*: 2014-03-20
    Sponsor Name:VU University Medical Centre
    Full Title: The effect of high-resistance muscle strength training and vitamin D supplementation in persons with knee osteoarthritis
    Medical condition: knee osteoarthritis vitamin D deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003750-10 Sponsor Protocol Number: NA Start Date*: 2005-09-12
    Sponsor Name:VästraGötaland
    Full Title: Growth hormone and androgens in the treatment of glucocorticoid induced protein catabolism
    Medical condition: Chronic treatment with glucocorticoids (GCs) regardless of indication leads to marked protein catabolism that causes substantial debilitation which includes muscle wasting, weakness, skin fragility...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003899-13 Sponsor Protocol Number: NL65803.078.18 Start Date*: 2018-12-20
    Sponsor Name:
    Full Title: The effect of IntraDialytic Parenteral Nutrition on nutritional status and quality of life in hemodialysis patients
    Medical condition: Malnutrition / Sarcopenia (loss of muscle mass) in hemodialyse patients.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000576-33 Sponsor Protocol Number: RBN 542 Start Date*: 2006-06-13
    Sponsor Name:St Helens & Knowsley Hospitals NHS Trust [...]
    1. St Helens & Knowsley Hospitals NHS Trust
    2. Universtiy of Liverpool
    Full Title: Pilot Study to investigate the role of Glutamine in the early protective stress response
    Medical condition: Critical Illness
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005202-98 Sponsor Protocol Number: 80202135IIM2001 Start Date*: 2022-11-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants with Active Idiopathic Inflammatory Myo...
    Medical condition: Active Idiopathic Inflammatory Myopathies (IIM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10028640 Myopathies HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002213-60 Sponsor Protocol Number: GX1001 Start Date*: 2019-01-08
    Sponsor Name:Solid Biosciences Inc.
    Full Title: A randomized, controlled, open-label, single-ascending dose, phase I/II study to investigate the safety and tolerability, and efficacy of intravenous SGT-001 in male adolescents and children with D...
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-000624-25 Sponsor Protocol Number: ATYR1940-C-006 Start Date*: 2016-06-22
    Sponsor Name:aTyr Pharma, Inc.
    Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Fascioscapulohumeral Muscular Dystrophy
    Medical condition: Limb Girdle Muscular Dystrophy and Facioscapulohumeral Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10064087 Facioscapulohumeral muscular dystrophy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000755-40 Sponsor Protocol Number: ATB200-03 Start Date*: 2019-04-08
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Algluc...
    Medical condition: Adult Subjects With Late Onset Pompe Disease (LOPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10075702 Pompe's disease late onset LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) SE (Completed) HU (Completed) BE (Completed) SK (Completed) ES (Completed) NL (Completed) BG (Prematurely Ended) SI (Completed) GR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006948-65 Sponsor Protocol Number: Version 4 Start Date*: 2007-11-29
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: The effect of acidosis correction and exercise on tissue wasting and immune function in renal patients
    Medical condition: Chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002214-35 Sponsor Protocol Number: BY9010/CP-038 Start Date*: 2006-08-01
    Sponsor Name:ALTANA Pharma AG
    Full Title: Free, not protein-bound concentrations of budesonide in subcutaneous adipose tissue, muscle tissue, and serum after oral inhalation via Turbohaler®
    Medical condition: Phase I healthy volunteer study
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004554-42 Sponsor Protocol Number: TAMDMD Start Date*: Information not available in EudraCT
    Sponsor Name:University of Basel Children's Hospital, Division of Neuropediatrics
    Full Title: Tamoxifen in Duchenne muscular dystrophy: A multicenter, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Tamoxifen in Duchenne muscular dystrophy: A 48-week...
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000029-29 Sponsor Protocol Number: 95105003 Start Date*: 2018-12-11
    Sponsor Name:VU University Medical Center
    Full Title: Extra energy for hearts with a genetic defect: ENERGY trial
    Medical condition: Hypertrophic cardiomyopathy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001691-11 Sponsor Protocol Number: PTC124-GD-046-DMD Start Date*: 2020-03-06
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: Phase 2, Non-Interventional, Clinical Study to Assess Dystrophin Levels in Subjects With Nonsense Mutation Duchenne Muscular Dystrophy Who Have Been Treated With Ataluren for ≥9 Months
    Medical condition: Non-Sense Mutation Duchenne Muscular Dystrophy (nmDMD)
    Disease:
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000095-10 Sponsor Protocol Number: BATCP Start Date*: 2015-03-30
    Sponsor Name:Karolinska Institutet
    Full Title: Botulinum toxin-A as a treatment for chronic muscle-related pain in adults with spastic cerebral palsy: a randomized controlled trial.
    Medical condition: Spastic cerebral palsy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021257-39 Sponsor Protocol Number: PB-PG-0808-16319 Start Date*: 2011-07-26
    Sponsor Name:SWBH NHS Trust [...]
    1. SWBH NHS Trust
    2. Keele University
    Full Title: Is it clinically effective to treat arm flexor spasticity, with Botulinum toxin – type A (BoNTA) and physiotherapy, as soon as signs of abnormal muscle activity are observed? (A phase II study)
    Medical condition: Stroke.Spasticity.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005478-24 Sponsor Protocol Number: DYNE251DMD201 Start Date*: Information not available in EudraCT
    Sponsor Name:Dyne Therapeutics, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participan...
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: IE (Trial now transitioned) BE (Trial now transitioned) ES (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002269-77 Sponsor Protocol Number: IM101611 Start Date*: 2017-08-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in ...
    Medical condition: Idiopathic Inflammatory Myopathy (IIM; eg, Dermatomyositis [DM], Polymyositis [PM], autoimmune necrotizing myopathy)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10042753 Symptomatic inflammatory myopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) SE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 15:13:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA